Bota Bio raises $100M Series B Financing to advance sustainable biomanufacturing

August 1, 2021 |

In California and China, Bota Bio raised more than $100 million in an oversubscribed Series B funding round, which will be used to expand the company’s global operations and build out Bota Bio’s lab-to-pilot scale platform to facilitate the rapid scale-up and deployment of the company’s product pipeline in consumer goods, food, nutrition, and pharmaceutical products.

The financing was led by Sequoia Capital China. Other investors included previous backers Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners, and 5Y Capital, among others. This Series B financing brings Bota Bio’s total funding to $145 million to date.

Bota Bio has developed and deployed a technology platform known as the Bota Freeway that integrates advanced digital tools with lab automation. Bota Bio has also expanded synthetic biology’s design-build-test-learn cycle to include downstream process development and select non-traditional microbial strains, accelerating the design and evolution of enzymes and cell-based factories.

Print Friendly, PDF & Email


Category: Fuels

Thank you for visting the Digest.